What the Nursing Care Plan Builder actually produces

PRIORITY 1 (ACUTE): Ineffective tissue perfusion (peripheral) • Goal: Patient will demonstrate improved peripheral circulation evidenced by diminished neuropathic pain (target 4/10 or less per order), palpable pedal pulses, and intact skin integrity within 4 weeks. • Interventions: (1) Assess bilateral pedal pulses daily, skin temperature, color, sensation using 10g monofilament at each visit; report absent/weak pulses or new ulceration immediately to provider. (2) Teach foot inspection protocol (mirror use, daily check between toes/heels) and proper footwear selection (cushioned, closed-toe). (3) Educate on activity: encourage non-weight-bearing exercise (seated marches, arm circles) per order; avoid prolonged standing. (4) Monitor HbA1c trending; coordinate with provider for glucose targets and insulin adjustment rationale. (5) Skin care: apply prescribed emollient to dry skin; avoid NSAIDs per CKD status. Rationale: Peripheral neuropathy + diminished pulses + dry skin = high ulceration risk in CKD patient; early detection and glucose control reduce amputation risk. Safety: Do not assert specific glucose or BP targets beyond input-derived values; escalate new pulses loss or skin breakdown per facility protocol immediately. PRIORITY 2 (ACUTE): Acute pain (neuropathic, 7/10) • Goal: Pain reduced to 4/10 or less within 2 weeks, patient able to perform ADLs and night sleep uninterrupted per self-report. • Interventions: (1) Assess pain using 0–10 scale each visit (time, location, triggers, relieving factors); document in flow sheet. (2) Non-pharmacologic: elevate feet on pillow when seated/supine; cool water foot soaks per order; gentle massage to calves. (3) Coordinate with provider regarding analgesic regimen (avoid NSAIDs due to CKD stage 2; verify any prescribed agents do not worsen renal function). (4) Sleep hygiene: loose blanket over feet, quiet dark room, consistent bedtime. (5) Teach distraction (Spanish-language music, family visits) and positioning changes hourly. Rationale: Neuropathic pain is often refractory to NSAIDs; non-pharmacologic + medication alignment + sleep support improve tolerance and function. Safety: Do not recommend specific drug classes or doses; defer to provider order and facility pain protocol. PRIORITY 3 (CHRONIC): Deficient knowledge regarding diabetes management, medication adherence, and CKD progression • Goal: Patient will verbalize understanding of insulin injection technique, home glucose monitoring, dietary sodium/protein restriction, and CKD warning signs within 1 week; demonstrate insulin self-injection by visit 3; achieve 80% adherence over 4 weeks per pharmacy refill audit. • Interventions: (1) Assess literacy level and preferred learning style (Spanish-language materials prioritized; use teach-back method in Spanish where available). (2) Provide structured education: (a) Insulin administration: use demo pen/syringe with saline, observe return demonstration twice. (b) Home glucose monitoring: provide log sheet (Spanish-labeled), target range per provider order (note: input shows HbA1c 9.4%—escalate glycemic control targets to provider). (c) CKD education: explain connection between BP control, diabetes, kidney function; warning signs (dark urine, swelling, fatigue, nausea). (d) Dietary: refer to renal dietitian; sodium <2300 mg/day, protein adjustment per eGFR and provider order [not provided—verify]. (3) Provide written materials in Spanish; reinforce at each visit. (4) Address barriers: transportation (coordinate community van or telehealth follow-up), cost (connect to copay assistance programs, community resources). (5) Simplify regimen if possible (coordinate with provider for once-daily vs. multiple injections). Rationale: Low health literacy + non-adherence + fixed income + language barrier are major barriers to diabetes and CKD control; tailored, multimodal education with material support improves outcomes and delays progression to dialysis. PRIORITY 4 (CHRONIC): Risk for ineffective self-management and social isolation (secondary to fixed income, limited transportation, language barrier) • Goal: Patient will identify 2 community resources (Spanish-language support group, food bank, telehealth option) within 2 weeks; report increased social contact (phone call with family member weekly or in-person visit monthly) within 4 weeks. • Interventions: (1) Assess social support system and transportation availability at baseline visit. (2) Provide resource list: local food bank, community health center with Spanish-language services, diabetes support group (in-person or virtual in Spanish). (3) Establish telehealth visits where available to reduce transportation burden. (4) Connect with case management/social work for financial assistance, medication programs, medical equipment subsidies. (5) Encourage family involvement: provide education handouts for caregiver; suggest weekly phone check-in or monthly visit. Rationale: Social determinants (fixed income, transportation, language) are primary barriers to adherence and self-management in chronic disease; addressing these directly improves engagement and outcomes. PRIORITY 5 (CHRONIC): Risk for disease progression and dialysis initiation • Goal: eGFR decline slowed or stabilized over 12 weeks; urine protein trending downward if proteinuria present [not provided—verify]; BP consistently <130/80 mmHg per provider order; no acute kidney injury events. • Interventions: (1) Monitor and document BP each visit (input: 158/94—elevated; target per provider order). (2) Ensure baseline and periodic labs per facility protocol: serum creatinine, eGFR, electrolytes, phosphorus, parathyroid hormone [specific intervals—verify with provider/protocol]. (3) Educate on medication adherence (antihypertensive, any SGLT2 inhibitor or ACE inhibitor if prescribed, calcium phosphate binder if indicated [all per provider order—not asserted]). (4) Restrict sodium and adjust protein intake per renal dietitian; avoid NSAIDs and nephrotoxic agents. (5) Avoid contrast agents unless essential and with hydration per protocol. (6) Teach warning signs: dark urine, extreme fatigue, persistent nausea, swelling, orthopnea; route to provider immediately. Rationale: Stage 2 CKD with diabetes + hypertension + non-adherence = high progression risk; early aggressive management of BP, glucose, proteinuria, and lifestyle factors can slow or halt progression. Safety: All lab frequencies, BP targets, medication classes, and dialysis-risk thresholds are patient-specific and provider-dependent; do not assert timelines or criteria beyond these.

1. Ineffective tissue perfusion (peripheral) [NANDA-I 00204] Defining characteristics: Diminished pedal pulses bilaterally, numbness and burning pain bilateral feet (7/10), dry skin, BMI 31.2 (obesity). Related factors: Diabetes mellitus with neuropathy, hypertension, CKD stage 2, non-adherence to insulin (HbA1c 9.4%). Priority: ACUTE—risk of ulceration, infection, amputation. 2. Acute pain (neuropathic) [NANDA-I 00131] Defining characteristics: Self-reported pain 7/10 in bilateral feet, described as burning and numbness, affecting ADL and sleep (implied). Related factors: Peripheral neuropathy secondary to Type 2 DM, ischemia (diminished pulses), CKD contributing to neuropathy progression. Priority: ACUTE—impacts function and quality of life; risk of depression, non-adherence. 3. Deficient knowledge (diabetes management, medication adherence, CKD progression) [NANDA-I 00161] Defining characteristics: Non-adherence to insulin regimen, low health literacy noted, HbA1c 9.4% (indicating suboptimal glucose control), inability to perform self-care per assessment. Related factors: English as second language (Spanish primary), low health literacy, complex regimen, fixed income limiting access to education resources. Priority: CHRONIC—foundational barrier to all self-management; addresses root cause of poor control. 4. Risk for ineffective self-management and social isolation [NANDA-I 00198 (self-management) + 00054 (isolation)] Risk factors: Lives alone, fixed income, limited transportation, English as second language, chronic disease burden, low health literacy. Priority: CHRONIC—psychosocial barrier; linked to adherence, depression, and outcomes. 5. Risk for disease progression to ESRD/dialysis dependency [NANDA-I 00180 (risk for infection) + broader risk] Risk factors: Stage 2 CKD + diabetes + hypertension (BP 158/94) + non-adherence + obesity (BMI 31.2). Priority: CHRONIC—long-term prevention goal aligned with patient goal to "avoid dialysis long-term."

WEEK 1 (BASELINE & ACUTE ASSESSMENT): • Day 1: Full foot/vascular assessment (pulses, sensation, skin integrity, temperature, color); pain assessment (0–10 scale, trigger log); social/economic screen; identify Spanish-language resources; establish baseline labs per facility protocol (eGFR, creatinine, HbA1c trend—per order). • Day 1–3: Teach-back insulin administration (demo + return demonstration); distribute Spanish-language foot care & diabetes basics handout; arrange telehealth vs. in-person preference; connect with case management. • Day 3–7: Pain intervention trial (elevation, soaks, non-pharmacologic); assess sleep and ADL impact; contact provider to confirm glucose targets, pain regimen (avoid NSAIDs), BP goals; verify any prescribed agents safe in CKD. WEEK 2–3 (EDUCATION & INTERVENTION TITRATION): • Twice weekly: Pain reassessment (0–10), foot check, insulin adherence review (use teach-back on injection sites, timing); home glucose log review (target range per order). • Week 2: Second insulin demonstration if needed; begin foot inspection protocol (mirror demo); CKD education part 1 (kidney function, DM-HTN-CKD connection); refer to renal dietitian (sodium, protein). • Week 3: Assess pain trajectory; if still >5/10, escalate to provider for medication review or neuropathy specialist referral per facility protocol. Document resource uptake (support group registered? food bank enrollment?). WEEK 4–12 (MAINTENANCE & MONITORING): • Monthly visits: Reassess pain, pedal pulses, skin integrity, glucose log review, BP (target per order), medication adherence (refill audit), social support engagement, lab monitoring per protocol. • Month 2: Repeat foot exam + sensation testing; reinforce dietary adherence; assess for any neuropathy progression (new areas of numbness, ulceration—escalate immediately). Verify eGFR/creatinine trending. • Month 3: Full reassessment; review HbA1c (goal per provider—improve from 9.4%); assess pain reduction (target ≤4/10); confirm dialysis-prevention education absorbed; adjust interventions based on progress checkpoints. ESCALATION TRIGGERS (IMMEDIATE PROVIDER CONTACT OR FACILITY PROTOCOL): • New or worsening foot ulcer, infected area, or loss of pedal pulses. • Uncontrolled pain despite interventions (>7/10 or new localization). • Signs of acute kidney injury: creatinine rise >0.3 mg/dL from baseline, reduced urine output, dark urine. • Hyperglycemia >350 mg/dL, symptoms of DKA (nausea, vomiting, fruity breath), or hypoglycemia (<70 mg/dL) unresponsive to treatment. • Suicidal ideation, severe depression, or refusal of care. • Non-adherence with barriers identified that case management cannot address.